Phase 3 · Exenatide

NCT00679042 trial results

Islet Transplantation in Type 1 Diabetic Patients Using the UIC Protocol, Phase 3

Participants
21
Status
completed
Completed
2026-07-01
Sponsor
CellTrans Inc.

As posted on ClinicalTrials.gov (NCT00679042), updated at source Nov 4, 2026. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.

Primary outcome

What NCT00679042 measured first

Treatment Emergent Adverse EventsParticipants · From first islet transplant through one year after last transplant (maximum 3 infusions possible), an average of 1 year · count of participants
MeasureTreatmentn=21
TEAE21
Serious TEAE11
TEAEs rated as severe or beyond16
TEAEs leading to death or discontinuation0
Number of Subjects Reaching the Efficacy GoalParticipants · One year after islet transplant · count of participants
MeasureTreatmentn=21
Success at 1 yr post first transplant8
Success at 1 yr post last transplant11
Side effects by arm

Side effects in NCT00679042

Percent of participants affected, From first islet transplant through one year after last transplant (maximum 3 infusions possible), an average of 1 year.. The most common events the registry lists.

EventTreatment
Any serious event52.4%
Vomiting81%
fatigue76.2%
anemia71.4%
asthenia66.7%
acne66.7%
Abnormal loss of weight61.9%
diarrhea61.9%
Headache57.1%
Transaminases increased47.6%
Oropharyngeal pain47.6%
Hypoalbuminaemia42.9%
Hyponatraemia42.9%
Dizziness42.9%
Rash42.9%
Stomatitis38.1%
Insomnia38.1%
Nasal congestion38.1%
Pruritus38.1%
Mouth ulceration33.3%
Upper respiratory tract infection33.3%
Contusion33.3%
Hypocalcaemia33.3%
Cough33.3%
Leukopenia28.6%
Hypomagnesaemia28.6%
Secondary outcomes

What else it measured

Number of Patients Presenting With Insulin Independence at Day 365 Post First and Last TransplantParticipants · 1 year after islet infusion · count of participants
MeasureTreatmentn=21
First Tx Day 365 Absence of exogenous insulin10
Last Tx Day 365 Absence of exogenous insulin12
First Tx Day 365 Fasting capillary glucose in a week not exceeding 140 mg/dL more than 3X7
Last Tx Day 365 Fasting capillary glucose in a week not exceeding 140 mg/dL more than 3X4
First Tx Day 365 Fasting plasma glucose ≤126 mg/dL10
Last Tx Day 365 Fasting plasma glucose ≤126 mg/dL11
First Tx Day 365 Post-prandial capillary glucose in a week: Not exceeding 180 mg/dL more than 1X/7X5
Last Tx Day 365 Post-prandial capillary glucose in a week: Not exceeding 180 mg/dL more than 1X/7X3
First Tx Day 365 C-peptide (fasting or stimulated) ≥0.5 ng/mL10
Last Tx Day 365 C-peptide (fasting or stimulated) ≥0.5 ng/mL10
Hypoglycemic Episodes by HYPO Scorescore on a scale · One year after the last transplant · median
MeasureTreatmentn=21
Baseline (pre-Tx)266(2 to 1638)
First Tx Day 36540.6(0 to 1234)
Last Tx Day 36518.7(0 to 1234)
Reduction in Hypoglycemic Severity Measured by %Reduction in HYPO Scorepercentage of HYPO baseline · One year after the first and last transplant · mean
MeasureTreatmentn=21
% Reduction from baseline to first tx day 36566.1(-300 to 100)
% Reduction from baseline to last tx day 36590.1(-106 to 100)
The trial

How NCT00679042 was run

In an earlier Phase 1/2 clinical trial using the Edmonton Protocol of steroid free immunosuppression, investigators at University of Illinois at Chicago (UIC) demonstrated the safety of islet preparation, iset transplantation, and medical treatment at UIC. Therefore, the primary purpose of the present Phase 3 clinical trial is to demonstrate the safety and efficacy of allogeneic islet transplantation in improving glycemic control in Type 1 diabetic patients using the UIC protocol that was developed and proven effective during the Phase 1/2 clinical trial.

  • Treatment: All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.
Who could join the trial

Inclusion Criteria: * Type 1 diabetes mellitus for more than 5 years complicated by the following situations that persist despite intensive insulin management efforts: * At least one episode of severe hypoglycemia in the past 3 years defined as an event with symptoms compatible with hypoglycemia in which the subject required the assistance of another person, and which was associated with either a blood glucose level \<50 mg/dL (2.8 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration * Reduced awareness of hypoglycemia, defined by the absence of adequate autonomic symptoms at capillary glucose levels of \<54 mg/dL (3 mmol/l) as reported by the subject Exclusion Criteria: * Co-existing cardiac disease: myocardial infarction within the past 6 months, angiographic evidence of non-correctable coronary artery disease, ischemia on functional cardiac exam, heart failure * Active alcohol or substance abuse, including cigarette smoking (must be abstinent for six months) * Psychiatric disorder: schizophrenia, bipolar disorder, or major depression that is unstable on medication * History of non-adherence to prescribed regimens * Active infection including hepatitis C, hepatitis B, HIV * TB by history, current infection, or under treatment for suspected TB * History of malignancies except squamous or basal skin cancer * Family history of MEN2 or MCT * Stroke within the past 6 months * BMI \>27 kg/m2 * C-peptide response to glucagon stimulation, any C-peptide \>0.3 ng/mL * Inability to provide informed consent * Age less than 18 or greater than 75 years * Creatinine clearance \<80 mL/min/1.73 m2 by 24-hour urine collection * Serum creatinine consistently \>1.5 mg/dL * Macroalbuminuria \>300 mg/24h * Baseline Hb \<12 gm/dL in women, \<13 gm/dL in men * Baseline liver function tests outside normal range * Untreated proliferative retinopathy * Positive pregnancy test, intent for pregnancy, male's intent to procreate, unwilling to use effective contraception, breast feeding * Previous transplant or PRA reactivity \>80% * Insulin requirement \>0.7 IU/kg/day * HbA1c \>12% * Hyperlipidemia (fasting cholesterol \>130 mg/dL or fasting triglycerides \>200 mg/dL * Medical condition requiring chronic use of steroids * Use of Coumadin or other antiplatelet or anticoagulant therapy, or PT-INR \>1.5 * Factor V deficiency * Smoking tobacco * Addison's disease * Allergy to radiographic contrast material * Symptomatic cholecystolithiasis * Acute or chronic pancreatitis * Symptomatic peptic ulcer disease * Severe unremitting diarrhea, vomiting, or other gastrointestinal disorders that could interfere with medication absorption * Treatment with antidiabetic medication other than insulin within 4 weeks of enrollment * Use of any study medication within 4 weeks of enrollment * Received live attenuated vaccine(s) within 2 months of enrollment * Any medical condition that, in the opinion of the investigator, might interfere with...

Published papers

Papers from NCT00679042

Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.